Pulling SEC filings + quote and writing the call…

Veradermics, Inc
Next earnings ≈ Aug 11, 2026 · est. from filing cadence
Last earnings -3.9% on 2026-05-12
Single-asset clinical-stage biotech with no revenue trading at ~6.9x IPO price — binary Phase 3 readout dominates everything.
Veradermics is a clinical-stage biopharma with zero product revenue, an accumulated deficit of $123.4M, and a single lead asset (VDPHL01, an extended-release oral minoxidil for pattern hair loss) carrying the entire equity story. FY2025 net loss widened to $70.0M from $26.5M (YoY -164.3%) as R&D scaled to $62.1M (+166.6%) ahead of two registration-directed trials. Operating cash burn of $71.6M against just $21.8M of cash at year-end would have been existential, but the 10-K discloses a Q4 2025 Series C raising $151.0M gross and a Q1 2026 IPO netting $269.7M at $17.00/share — together extending runway materially beyond the balance-sheet snapshot.
Sources: SEC EDGAR (CIK 0001827635, latest 10-Q filed 2026-05-12) · EODHD · analysis by claude-code · as of 6/25/2026, 12:45:29 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY24 | FY25 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | -$26.8M | -$72.3M |
| Net income | -$26.5M | -$70.0M |
| Diluted EPS | -$37.05 | -$111.91 |
| Net margin | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
First post-IPO 10-Q; $269.7M IPO proceeds bolster runway against rising trial spend
First post-IPO 10-Q; $269.7M IPO proceeds bolster runway against rising trial spend
Entered material agreement with unregistered equity issuance — potential licensing/financing deal
Filed resale S-1 registering pre-IPO holders' shares — overhang risk for float
Filed resale S-1 registering pre-IPO holders' shares — overhang risk for float
Filed resale S-1 registering pre-IPO holders' shares — overhang risk for float
FY2025 loss $70M, accumulated deficit $123M; sole asset VDPHL01 in Phase 3 trials
FY2025 loss $70M, accumulated deficit $123M; sole asset VDPHL01 in Phase 3 trials
Filed amended charter/bylaws post-IPO closing — routine governance cleanup
1070 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 11.2K @ $35.97 | $402K |
| 2026-02-06 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 19.3K @ $36.55 | $707K |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 3.83K @ $36.07 | $138K |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 19.2K @ $36.93 | $709K |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 38.8K @ $37.63 | $1.46M |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 17.8K @ $38.67 | $690K |
| 2026-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC Director | Buy | 16.6K @ $39.80 | $659K |
| 2026-02-05 | Grant-Kels Jane M. Director | Acquired (C) | 2.46K | |
| 2026-02-05 | Coric Vlad Director | Acquired (C) | 33.7K | |
| 2026-02-05 | Coric Vlad Director | Acquired (C) | 33.7K | |
| 2026-02-05 | Coric Vlad Director | Acquired (C) | 149K | |
| 2026-02-05 | Coric Vlad Director | Acquired (C) | 149K |